NCT05238831 - SMMART Adaptive Clinical Treatment (ACT) Trial | Biotech Hunter

Timeline

Start Date

January 30, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Advanced Breast CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian CarcinomaAdvanced Pancreatic CarcinomaAdvanced Prostate CarcinomaAdvanced SarcomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Recurrent Adult Soft Tissue SarcomaRecurrent Breast CarcinomaRecurrent Ovarian CarcinomaRecurrent Prostate CarcinomaStage II Pancreatic Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8

Interventions

DRUG

Alectinib

Given orally (PO)

DRUG

Alpelisib

Given PO

DRUG

Anastrozole

Given PO

BIOLOGICAL

Atezolizumab

Given IV

BIOLOGICAL

Bevacizumab

Given IV

PROCEDURE

Biopsy

Undergo tissue biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood

DRUG

Capecitabine

Given PO

DRUG

Carboplatin

Given IV

DRUG

Cobimetinib

Given PO

DRUG

Entrectinib

Given PO

DRUG

Eribulin

Given IV

DRUG

Fulvestrant

Given by injection

BIOLOGICAL

Hyaluronidase-zzxf/Pertuzumab/Trastuzumab

Given phesgo SC

DRUG

Irinotecan

Given IV

DRUG

Letrozole

Given PO

DRUG

Nab-paclitaxel

Given IV

DRUG

Niraparib

Given PO

DRUG

Olaparib

Given PO

DRUG

Paclitaxel

Given IV

DRUG

Palbociclib

Given IV

BIOLOGICAL

Pertuzumab

Given subcutaneously (SC)

OTHER

Quality-of-Life Assessment

Ancillary studies

BIOLOGICAL

Trastuzumab

Given SC

BIOLOGICAL

Trastuzumab Emtansine

Given intravenously (IV)

DRUG

Vemurafenib

Given PO

DRUG

Vinorelbine

Given IV

DRUG

Vismodegib

Given PO